Skip to main content
Bert Vogelstein, MD, Pediatrics, Baltimore, MD

BertVogelsteinMD

Pediatrics • Baltimore, MD

Professor of Oncology, Professor of Pathology, Joint of Molecular Biology and Genetics, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Vogelstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Vogelstein's full profile

Already have an account?

  • Office

    1650 Orleans St
    Crb1, Room 589
    Baltimore, MD 21287
    Phone+1 410-955-8878

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Pediatrics, 1974 - 1976
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1974

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1974 - 2023

Awards, Honors, & Recognition

  • Elected Member Institute of Medicine, 2001
  • Elected Member The American Society for Clinical Investigation, 1986
  • Whos Who in Medicine and Healthcare Marquis Whos Who
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Original Contribution Targeted Sequencing of Plasmacytoid Urothelial Carcinoma Reveals Frequent TERT Promoter Mutations☆  
    Morgan Cowan, Bert Vogelstein, Trinity J Bivalacqua, Gunes Guner, ScienceDirect
  • Minimal Functional Driver Gene Heterogeneity Among Untreated Metastases  
    Marc A Attiyeh, Bert Vogelstein, Zachary A Kohutek, Science Magazine
  • Reconstructing Metastatic Seeding Patterns of Human Cancers  
    Bert Vogelstein, MD, Nature

Press Mentions

  • FDA Approves Drug That Targets Brain Cancer Gene Mutation That Could Delay Need for Radiation and Chemotherapy
    FDA Approves Drug That Targets Brain Cancer Gene Mutation That Could Delay Need for Radiation and ChemotherapyAugust 17th, 2024
  • See the 25-Slide Pitch Deck a Baltimore Biotech Used to Raise $56 Million to Develop a Blood Test That Detects Recurring Cancer
    See the 25-Slide Pitch Deck a Baltimore Biotech Used to Raise $56 Million to Develop a Blood Test That Detects Recurring CancerNovember 16th, 2022
  • Better Cancer Screenings Are Coming. Can We Afford Them?
    Better Cancer Screenings Are Coming. Can We Afford Them?October 24th, 2022
  • Join now to see all

External Links

Dr. Bert Vogelstein, Dr. Bert Vogelstein, MD, Dr. B Vogelstein